Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DEGS1 | O15121 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | USP7 | Q93009 | 1/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10992923 | 0.79 | ESR1 (0.31) | — | |
| SCHEMBL10991767 | 0.75 | — | — | |
| SCHEMBL10600401 | 0.74 | TRPV4 (0.32) | TRPV4 | |
| SCHEMBL1169515 | 0.74 | HTT (0.35) | TRPV4AURKA | |
| SCHEMBL20003501 | 0.72 | TRPV4 (0.52) | TRPV4 | |
| SCHEMBL156478 | 0.72 | HTT (0.39) | TRPV4 | |
| SCHEMBL254676 | 0.72 | APLNR (0.39) | TRPV4 | |
| SCHEMBL10775633 | 0.72 | TRPV4 (0.31) | TRPV4 | |
| SCHEMBL17619921 | 0.72 | TRPV4 (0.31) | TRPV4 | |
| SCHEMBL14865436 | 0.72 | TRPV4 (0.31) | TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111533699-B | Synthesis method of 2- (trifluoromethyl) pyrimidine-5-alcohol | 龙曦宁（上海）医药科技有限公司 | 2023-12-01 | — | — | CN | claimed |
| CN-111533699-A | Synthetic method of 2- (trifluoromethyl) pyrimidine-5-ol | 龙曦宁（上海）医药科技有限公司 | 2020-08-14 | — | — | CN | claimed |
| EP-0213377-B1 | PHOSPHORIC (PHOSPHONIC) ACID ESTERS | BAYER AG (DE) | 1989-02-15 | — | — | EP | claimed |
| EP-0213377-A1 | Phosphoric (phosphonic) acid esters | BAYER AG (DE) | 1987-03-11 | — | — | EP | claimed |
| US-4558039-A | SYSTEMIC AND FOLIAR ACTIVITY FOR PLANTS AGAINST INSECT PESTS | THE DOW CHEMICAL COMPANY (US) | 1985-12-10 | — | — | US | claimed |
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | disclosed |
| US-12630551-B2 | Endocyclic pyrimidinone compounds, and preparation methods, compositions and use thereof | NEUSCO BIOTECH LIMITED (CN) | 2026-05-19 | — | — | US | disclosed |
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2026-05-14 | — | — | US | disclosed |
| US-12622917-B2 | High-activity Wnt pathway inhibitor compound | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2026-05-12 | — | — | US | disclosed |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | NOVARTIS PHARMA AG (CH) | 2025-12-23 | — | — | US | disclosed |
| US-12384790-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-08-12 | — | — | US | disclosed |
| WO-2025151724-A1 | PYRIDINYLOXYPYRIDINES AS MODULATORS OF ATP -BINDING CASSETTE TRANSPORTERS AND THEIR USE IN TREATING MEDICAL CONDITIONS | RECTIFY PHARMACEUTICALS, INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| WO-2006065216-A1 | NOVEL HYDANTOIN DERIVATIVES AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006004532-A1 | NOVEL HYDANTOIN DERIVATIVES FOR THE TREATMENT OF OBSTRUCTIVE AIRWAY DISEASES | ASTRAZENECA AB (SE) | 2006-01-12 | — | — | WO | disclosed |
| WO-2005095362-A1 | TRIAZOLONE DERIVATIVES AS MMP INHIBITORS FOR THE TREATMENT OF ASTHMA AND COPD | ASTRAZENECA AB (SE) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005095330-A1 | NOVEL DICHLOROPROPENE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2005-10-13 | — | — | WO | disclosed |
| EP-0213377-B1 | PHOSPHORIC (PHOSPHONIC) ACID ESTERS | BAYER AG (DE) | 1989-02-15 | — | — | EP | disclosed |
| US-4774233-A | Pesticidally active O-ethyl O-isopropyl O-(2-trifluoromethylpyrimidin-5-yl)-phosphoric acid ester | BAYER AKTIENGESELLSCHAFT (DE) | 1988-09-27 | — | — | US | disclosed |
| EP-0213377-A1 | Phosphoric (phosphonic) acid esters | BAYER AG (DE) | 1987-03-11 | — | — | EP | disclosed |
| US-4558039-A | SYSTEMIC AND FOLIAR ACTIVITY FOR PLANTS AGAINST INSECT PESTS | THE DOW CHEMICAL COMPANY (US) | 1985-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137680-A1 | NOVEL COMPOUNDS | CCR1, CCR4, CCR3 | DEGS1 716/4885KIF11 4152/4885USP7 3903/4885 |
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, IRF3, CGAS | DEGS1 385/4885KIF11 4488/4885USP7 2883/4885 |
| US-12622917-B2 | High-activity Wnt pathway inhibitor compound | WNT1, WNT3, WNT3A | DEGS1 1111/4885KIF11 4553/4885USP7 3250/4885 |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, CGAS, IRF3 | DEGS1 1844/4885KIF11 4125/4885USP7 1591/4885 |
| US-12630551-B2 | Endocyclic pyrimidinone compounds, and preparation methods, compositions and use thereof | LPAR1, PLA2R1, LPAR2 | DEGS1 106/4885KIF11 4741/4885USP7 3575/4885 |
| US-12384790-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | DEGS1 3635/4885KIF11 2629/4885USP7 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.